Home 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 PD-1/IL-2α-Bias Bispecific Fusion Protein Demonstrates Robust Survival Benefits in IO-Resistant NSCLC

2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 PD-1/IL-2α-Bias Bispecific Fusion Protein Demonstrates Robust Survival Benefits in IO-Resistant NSCLC

May 22, 2026 07:49 CST Updated 08:06